NASDAQ:GERN - Geron Stock Price, Price Target & More

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company had revenue of $0.32 million for the quarter. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. During the same quarter in the prior year, the firm earned ($0.05) EPS. View Geron's Earnings History.

Geron is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Geron.

5 equities research analysts have issued 12 month price targets for Geron's shares. Their predictions range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.5833 in the next year. This suggests a possible upside of 61.8% from the stock's current price. View Analyst Ratings for Geron.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Geron saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 52,712,240 shares, an increase of 18.2% from the June 15th total of 44,580,747 shares. Based on an average trading volume of 4,769,004 shares, the short-interest ratio is currently 11.1 days. Currently, 30.6% of the company's shares are short sold. View Geron's Current Options Chain.

Some companies that are related to Geron include Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH) and Phibro Animal Health (PAHC).

News coverage about GERN stock has been trending somewhat negative this week, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Geron earned a news sentiment score of -0.01 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $3.45.

Geron has a market capitalization of $626.55 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]